Guangdong Lifestrong Pharmacy Co. Ltd. (301111) - Net Assets
Based on the latest financial reports, Guangdong Lifestrong Pharmacy Co. Ltd. (301111) has net assets worth CN¥750.62 Million CNY (≈ $109.84 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥897.92 Million ≈ $131.39 Million USD) and total liabilities (CN¥147.30 Million ≈ $21.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See 301111 net asset quality score to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥750.62 Million |
| % of Total Assets | 83.6% |
| Annual Growth Rate | 20.74% |
| 5-Year Change | 0.05% |
| 10-Year Change | N/A |
| Growth Volatility | 42.2 |
Guangdong Lifestrong Pharmacy Co. Ltd. - Net Assets Trend (2017–2025)
This chart illustrates how Guangdong Lifestrong Pharmacy Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 301111 market cap.
Annual Net Assets for Guangdong Lifestrong Pharmacy Co. Ltd. (2017–2025)
The table below shows the annual net assets of Guangdong Lifestrong Pharmacy Co. Ltd. from 2017 to 2025. Also explore Guangdong Lifestrong Pharmacy Co. Ltd. equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥751.22 Million ≈ $109.93 Million |
-2.03% |
| 2024-12-31 | CN¥766.75 Million ≈ $112.20 Million |
-1.47% |
| 2023-12-31 | CN¥778.21 Million ≈ $113.88 Million |
+2.57% |
| 2022-12-31 | CN¥758.67 Million ≈ $111.02 Million |
+1.04% |
| 2021-12-31 | CN¥750.85 Million ≈ $109.87 Million |
+132.17% |
| 2020-12-31 | CN¥323.41 Million ≈ $47.32 Million |
+19.04% |
| 2019-12-31 | CN¥271.68 Million ≈ $39.76 Million |
+18.14% |
| 2018-12-31 | CN¥229.97 Million ≈ $33.65 Million |
+38.23% |
| 2017-12-31 | CN¥166.37 Million ≈ $24.34 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Lifestrong Pharmacy Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 569.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥149.68 Million | 19.94% |
| Other Components | CN¥601.01 Million | 80.06% |
| Total Equity | CN¥750.69 Million | 100.00% |
Guangdong Lifestrong Pharmacy Co. Ltd. Competitors by Market Cap
The table below lists competitors of Guangdong Lifestrong Pharmacy Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Solowin Holdings Ordinary Share
NASDAQ:SWIN
|
$492.41 Million |
|
B&S Group SA
AS:BSGR
|
$492.44 Million |
|
Kaufman Et Broad
PA:KOF
|
$493.11 Million |
|
goeasy Ltd
TO:GSY
|
$493.40 Million |
|
Shanghai Phoenix Enterprise Group Co Ltd A
SHG:600679
|
$492.37 Million |
|
Guizhou Transp Planning
SHG:603458
|
$491.86 Million |
|
Rayonier Advanced Materials
NYSE:RYAM
|
$491.82 Million |
|
Guangdong Sanhe Pile Co Ltd
SHE:003037
|
$491.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Lifestrong Pharmacy Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 764,337,228 to 750,692,567, a change of -13,644,661 (-1.8%).
- Net loss of 4,488,758 reduced equity.
- Dividend payments of 8,000,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-4.49 Million | -0.6% |
| Dividends Paid | CN¥8.00 Million | -1.07% |
| Other Changes | CN¥-1.16 Million | -0.15% |
| Total Change | CN¥- | -1.79% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Lifestrong Pharmacy Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.17x to 4.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.39 | CN¥21.03 | x |
| 2018-12-31 | CN¥1.92 | CN¥21.03 | x |
| 2019-12-31 | CN¥2.28 | CN¥21.03 | x |
| 2020-12-31 | CN¥2.69 | CN¥21.03 | x |
| 2021-12-31 | CN¥6.30 | CN¥21.03 | x |
| 2022-12-31 | CN¥4.77 | CN¥21.03 | x |
| 2023-12-31 | CN¥4.87 | CN¥21.03 | x |
| 2024-12-31 | CN¥5.51 | CN¥21.03 | x |
| 2025-12-31 | CN¥4.69 | CN¥21.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Lifestrong Pharmacy Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.43%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 1.19x
- Recent ROE (-0.60%) is below the historical average (11.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 19.69% | 17.10% | 0.68x | 1.69x | CN¥16.12 Million |
| 2018 | 27.66% | 21.89% | 0.98x | 1.29x | CN¥40.60 Million |
| 2019 | 24.53% | 21.05% | 0.97x | 1.20x | CN¥39.46 Million |
| 2020 | 19.33% | 18.34% | 0.89x | 1.19x | CN¥30.18 Million |
| 2021 | 7.62% | 16.35% | 0.42x | 1.10x | CN¥-17.90 Million |
| 2022 | 4.40% | 11.79% | 0.33x | 1.13x | CN¥-42.45 Million |
| 2023 | 4.32% | 11.46% | 0.34x | 1.10x | CN¥-44.12 Million |
| 2024 | 0.54% | 1.49% | 0.30x | 1.22x | CN¥-72.27 Million |
| 2025 | -0.60% | -1.43% | 0.35x | 1.19x | CN¥-79.56 Million |
Industry Comparison
This section compares Guangdong Lifestrong Pharmacy Co. Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,159,462,338
- Average return on equity (ROE) among peers: 8.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Lifestrong Pharmacy Co. Ltd. (301111) | CN¥750.62 Million | 19.69% | 0.20x | $492.38 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $5.88 Billion | 7.12% | 1.83x | $577.52 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $407.99 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $793.34 Million | 10.94% | 0.24x | $4.35 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $275.56 Million | 21.50% | 1.16x | $2.29 Billion |
| Wedge Industrial Co Ltd (000534) | $654.70 Million | 1.92% | 0.87x | $1.74 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $13.25 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.49 Billion | 5.19% | 0.85x | $861.90 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $347.80 Million | 3.58% | 0.72x | $308.02 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $869.73 Million | 4.99% | 1.99x | $964.68 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $9.75 Billion | 6.63% | 0.12x | $3.04 Billion |
About Guangdong Lifestrong Pharmacy Co. Ltd.
Guangdong Lifestrong Pharmacy Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products. It operates through Medical Services and Health Management; and Health Consumer Products segments. The company produces tablets, hard capsules, injections, and pills, and other related products. It also offers respiratory, pediatric, gynecology, urinary, and nutrition and… Read more